electroCoreECOR
About: electroCore Inc is a commercial stage bioelectronic medicine company with a platform for non-invasive vagus nerve stimulation therapy initially focused on neurology. The company's product gammaCore is Food and Drug Administration cleared in the United States for adjunctive use for the preventive treatment of cluster headache in adult patients, the acute treatment of pain associated with episodic cluster headache in adult patients, the acute treatment of pain associated with migraine headache in adult patients, and the prevention of migraine in adult patients, The use of gammaCore by adolescent patients and Treatment of hemicrania continua and paroxysmal hemicrania in adult patients.
Employees: 62
Fund manager confidence
Based on 2025 Q2 regulatory disclosures by fund managers ($100M+ AUM)
100% more repeat investments, than reductions
Existing positions increased: 10 | Existing positions reduced: 5
2.88% less ownership
Funds ownership: 18.66% [Q1] → 15.78% (-2.88%) [Q2]
11% less funds holding
Funds holding: 35 [Q1] → 31 (-4) [Q2]
31% less capital invested
Capital invested by funds: $8.97M [Q1] → $6.19M (-$2.78M) [Q2]
50% less first-time investments, than exits
New positions opened: 4 | Existing positions closed: 8
Research analyst outlook
We haven’t received any recent analyst ratings for ECOR.
Financial journalist opinion
Based on 6 articles about ECOR published over the past 30 days
